Indications
Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
Composition
- Active substance
- parathyroid hormone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Natpar
- Active substance
- parathyroid hormone
- ATC code
- H05AA03
- Therapeutic area
- Hypoparathyroidism
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland Branch
- Status
- Authorised
- EU authorisation